AUTHORS
Jackson Hans Bauer, Marco D Carpenter, PhD2, Olivia Katz, MD3, Kara Kennedy, MD4, Samantha H Wang5, Eric Lee6, Andy Wang7, Philip W Zoltick, MD8, Mohamad-Gabriel Alameh, PhD9, William Peranteau, MD10
AFFILIATIONS
1 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States, University of Pennsylvania, Philadelphia, Pennsylvania, United States
2 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
3 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
4 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
5 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
6 University of Pennsylvania, Philadelphia, Pennsylvania, United States
7 University of Pennsylvania, Philadelphia, Pennsylvania, United States
8 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
9 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States, University of Pennsylvania, Philadelphia, Pennsylvania, United States
10 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States, University of Pennsylvania, Philadelphia, Pennsylvania, United States
ABSTRACT
Introduction: Alpha thalassemia is a hematologic disorder caused by mutations in the alpha globin genes HBA1 and HBA2. These mutations cause loss of expression of functional alpha globin, which disrupts the ability of HbA hemoglobin tetramers to form in red blood cells and carry oxygen throughout the body. Severe cases require frequent blood transfusions or bone marrow transplant. Current gene therapy efforts focus on replacing alpha globin expression by ex vivo addition of a transgene via lentiviral vectors or CRISPR-Cas9 homology-directed repair. In vivo gene editing is a promising alternative approach that may precisely correct some pathogenic variants without requiring hematopoietic stem cell mobilization, apheresis, or myeloablative conditioning. Alpha thalassemia mutations can be either deletional, where large sections of genomic DNA around the HBA gene cluster are missing, or non-deletional, where small changes in the genomic DNA sequence such as nucleotide substitutions disrupt alpha globin expression, function, or stability. Non-deletional mutations are more easily corrected with current gene editing technologies such as base editing and prime editing. The Constant Spring (CS) mutation in HBA2 (c.427T>C) is the most common non-deletional mutation, accounting for approximately 5-10% of alleles that cause alpha thalassemia. This T>C mutation is amenable to correction by cytosine base editing (CBE) or prime editing (PE). We sought to optimize editing strategies to correct this mutation and to demonstrate the efficacy of these strategies in restoring alpha globin expression in human cells in vitro and in a mouse model.
Methods: We produced clonal K562 (human lymphoblast) and HUDEP2 (human erythroid progenitor) cell lines with the CS mutation by adenine base editing followed by isolation of clones by fluorescence-activated cell sorting. In the K562 cell line, we screened 63 combinations of plasmids expressing CBEs and sgRNAs and assessed correction of the CS mutation by next generation sequencing (NGS) to determine the most efficient editing strategy. Similarly, for prime editing, we screened 16 PE variants, 13 pegRNAs, and six ngRNAs. We also assessed the ability of 21 different hybrid guide RNAs, which incorporate DNA nucleotides into the guide’s spacer region, to reduce bystander editing for the CBE strategy. mRNA expressing the optimal CBE or PE was produced along with chemically synthesized sgRNA, pegRNA, and ngRNA for use in subsequent studies. We delivered this RNA to the HUDEP2 cell line to correct the CS mutation, then differentiated the HUDEP2 cells into red blood cells. Wild-type (WT) and CS mutant alpha globin mRNA levels were measured using droplet digital PCR and alpha globin protein expression was assessed by western blotting. A mouse model was generated with murine alpha globin genes replaced by a human WT or CS mutant alpha globin gene. Lipid nanoparticles (LNPs) carrying the optimal CBE mRNA and sgRNA were produced and injected into fetal mice at various doses and gestational ages to assess correction of the CS mutation in vivo. Editing in peripheral blood was assessed at 1, 2, and 3 months of age, and editing in bone marrow LT-HSCs was assessed at 3 months of age by NGS.
Results: The optimal CBE and PE strategies achieved up to 91% and 79% correction of the CS mutation in vitro, respectively. In the CBE approach, approximately 5% of corrected alleles also possessed a nonsynonymous bystander mutation. Hybrid guide RNAs reduced relative bystander editing up to 2-fold at the expense of slightly reduced editing of the target CS nucleotide. In HUDEP2 CS cells treated with editor RNA, WT alpha globin mRNA was restored to up to 79% of normal levels. Western blotting revealed restoration of WT alpha globin protein expression in a dose-dependent manner. LNP-mediated in vivo editing achieved up to 52% correction of the CS mutation in LT-HSCs.
Conclusion: Both cytosine base editing and prime editing achieve efficient correction of the HBA2 Constant Spring mutation in human cells in vitro. Correcting the mutation at the genomic level restores expression of WT alpha globin mRNA and protein. Efficient correction of the mutation was achieved in murine LT-HSCs by LNP delivery. This work lays the foundation for a gene editing therapy for alpha thalassemia patients with the most common non-deletional mutation.
DISCLOSURES
Jackson Hans Bauer: No relevant conflicts of interest to declare.